Cart
sales@molnova.com
PDE9-IN-(S)-C33
CAS No. 2066488-39-7
PDE9-IN-(S)-C33( PDE9IN(S)C33 | PDE9 IN (S) C33 | (S)-C33 )
Catalog No. M27911 CAS No. 2066488-39-7
PDE9-IN-(S)-C33 is a potent and selective inhibitor of PDE9 (IC50 = 11 nM). PDE9-IN-(S)-C33 can be used for central nervous system diseases and diabetes research.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 72 | In Stock |
|
| 5MG | 64 | In Stock |
|
| 10MG | 90 | In Stock |
|
| 25MG | 147 | In Stock |
|
| 50MG | 214 | In Stock |
|
| 100MG | 319 | In Stock |
|
| 200MG | 455 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NamePDE9-IN-(S)-C33
-
NoteResearch use only, not for human use.
-
Brief DescriptionPDE9-IN-(S)-C33 is a potent and selective inhibitor of PDE9 (IC50 = 11 nM). PDE9-IN-(S)-C33 can be used for central nervous system diseases and diabetes research.
-
DescriptionPDE9-IN-(S)-C33 is a potent and selective inhibitor of PDE9 (IC50 = 11 nM). PDE9-IN-(S)-C33 can be used for central nervous system diseases and diabetes research.
-
In Vitro——
-
In Vivo——
-
SynonymsPDE9IN(S)C33 | PDE9 IN (S) C33 | (S)-C33
-
PathwayAngiogenesis
-
TargetPDE
-
RecptorAdrenocorticotropic hormone (ACTH)
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2066488-39-7
-
Formula Weight357.84
-
Molecular FormulaC18H20ClN5O
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (279.45 mM)
-
SMILESC[C@H](Nc1nc2n(ncc2c(=O)[nH]1)C1CCCC1)c1ccc(Cl)cc1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Kita T, et al. Analgesic and other pharmacologic actions of saiko-saponin in repeated cold stressed (SART stressed) animals. J Pharmacobiodyn. 1980 Jun;3(6):269-80.
molnova catalog
related products
-
CDP-840 hydrochlorid...
CDP-840 (CDP840;L-765527) is a potent and selective PDE4 inhibitor with IC50 of 4-45 nM.
-
Mirodenafil
Mirodenafil is a PDE-5 inhibitor developed for the treatment of erectile dysfunction.The pharmacoki-netics of mirodenafil were not significantly altered by this concurrent administration. Mirodenafil (50 or 100 mg), obviously improved erectile function and was well tolerated in a representative population of Korean men with broad-spectrum ED of various etiologies and severities.
-
Cilomilast
A potent and selective PDE4 inhibitor with IC50 of 95/120 nM for LPDE4/HPDE4.
